Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Email me when HR 8890 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 8890. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill changes the CLIA law so that any laboratory‑developed test (LDT) must meet a federal standard for analytical and clinical validity before it can be used. It creates a process for third‑party or FDA review, adds error‑reporting requirements, and updates how Medicare and the FDA treat LDTs. The goal is to improve patient safety while keeping innovative tests available.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 8890
3 free questions a day, no accountSponsors
- Rep. Dunn, Neal P. [R-FL-2] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 8890 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 8890 freeOr ask your AI assistant about HR 8890 directly:
Add to Claude, ChatGPT or Cursor